Thermo Fisher Scientific revenue and financials

TMO · NYSE · USD

$656.58Change from previous close: −2.98%Absolute change: −$20.18

Close · October 6, 2026

In the fiscal year ended December 2025, Thermo Fisher Scientific reported revenue of $44.56B (+3.91% year over year). Net income was $6.7B, a net margin of 15.0%.

Annual revenue · 2025: $44.56B
  1. $18.27B2016
  2. $20.92B2017
  3. $24.36B2018
  4. $25.54B2019
  5. $32.22B2020
  6. $39.21B2021
  7. $44.92B2022
  8. $42.86B2023
  9. $42.88B2024
  10. $44.56B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+3.91%
2025 vs 2024
Net income growth
+5.82%
2025 vs 2024
Net margin
15.0%
2024: 14.8%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Cash flow · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Operating cash flow2,1251,1923,4572,2391,3997233,2902,1661,9601,2513,7232,414
Depreciation and amortization819734728671686705742750780836839853
Capital expenditure-450-376-465-404-294-362-480-272-301-347-405-332
Investing cash flow164-8,961891-4,123-288-52720.0-3,578-253-2,030-376-1,181
Financing cash flow-1,5711,0933,526-632-991-102-3,666-1,190-115-1,821-1,4281,855
Dividends paid-175-162-162-163-162-149-149-150-149-135-136-135
Share repurchases-1,000-3,000-37.0-9630.0-2,000-1,0000.00.0-3,000——
Debt issued0.05,6274,9191,0950.02,8400.00.0-1.01,2052,4763,466
Debt repaid-389-1,412-1,285-597-787-838-2,500-1,107——-3,782-1,494
Effect of exchange rates98.078.0-6.0-75.031137.0-273175-15.022.010.0-73.0
Net change in cash816-6,5997,868-2,592431132-630-2,4271,578-2,5781,9293,015
Free cash flow1,6758162,9921,8351,1053612,8101,8941,6599043,3182,082
Levered free cash flow1,4531,1422,1981,46674212.62,5001,8681,3058752,7051,585